Nxstage Medical, Inc. (NXTM) Tops Q4 EPS by 9c, Offers Weak Q1 and FY12 Guidance

Nxstage Medical, Inc. (NASDAQ: NXTM) reported Q4 EPS of $0.00, $0.09 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $57 million versus the consensus estimate of $56.21 million.

Nxstage Medical, Inc. sees Q1 2012 EPS of $-0.11-$-0.09, versus the consensus of $-0.06. Nxstage Medical, Inc. sees Q1 2012 revenue of $56-$57 million, versus the consensus of $57 million.

Nxstage Medical, Inc. sees FY2012 EPS of $-0.32-$-0.25, versus the consensus of $-0.13. Nxstage Medical, Inc. sees FY2012 revenue of $240-$245 million, versus the consensus of $245.13 million.

For earnings history and earnings-related data on Nxstage Medical, Inc. (NXTM) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Humana (HUM) surges on Q1 beat, reiterated adjusted earnings outlook
• Boston Scientific (BSX) Tops Q1 EPS by 5c; Guides Above Views
• Hilton hikes 2024 earnings outlook as Q1 results beat expectations, shares up